NCT01828021View on ClinicalTrials.gov

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 7, 2016

Study Completion Date

April 14, 2017

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Margetuximab

Anti-HER2 monoclonal antibody

Trial Locations (6)

33324

Florida Cancer Research Institute, Plantation

37203

Tennessee Oncology, Nashville

46202

Indiana University, Indianapolis

94115

University of California San Francisco, San Francisco

94305

Stanford University, Stanford

02111

Tufts Cancer Center, Boston

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
lead

MacroGenics

INDUSTRY

NCT01828021 - Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer | Biotech Hunter | Biotech Hunter